CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...